Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Advertisers
    • Editorial Board
    • Special Issues
  • Journal Metrics
  • Other Publications
    • Anticancer Research
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • In Vivo
    • Anticancer Research
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
In Vivo
  • Other Publications
    • In Vivo
    • Anticancer Research
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
In Vivo

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Advertisers
    • Editorial Board
    • Special Issues
  • Journal Metrics
  • Other Publications
    • Anticancer Research
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
  • About Us
    • General Policy
    • Contact
  • Visit iiar on Facebook
  • Follow us on Linkedin

Mivebresib

  • Open Access
    Co-clinical Modeling of the Activity of the BET Inhibitor Mivebresib (ABBV-075) in AML
    DANIEL H. ALBERT, NEAL C. GOODWIN, ANGELA M. DAVIES, JENNY ROWE, GEROLD FEUER, MICHAEL BOYIADZIS, KATHLEEN A. DORRITIE, MARIA MANCINI, REGINA GANDOUR-EDWARDS, BRIAN A. JONAS, GAUTAM BORTHAKUR, IBRAHIM ALDOSS, DAVID A. RIZZIERI, OLATOYOSI ODENIKE, THOMAS PREBET, SANJANA SINGH, RELJA POPOVIC, YU SHEN, KEITH F. MCDANIEL, WARREN M. KATI, DIMPLE A. MODI, MONICA MOTWANI, JOHANNES E. WOLFF and DAVID J. FROST
    In Vivo July 2022, 36 (4) 1615-1627; DOI: https://doi.org/10.21873/invivo.12872
In Vivo

© 2026 In Vivo

Powered by HighWire